ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Launched by STANFORD UNIVERSITY · Jul 25, 2016

Keywords

ClinConnect Summary

This clinical trial is focused on understanding mycosis fungoides and Sezary syndrome, which are rare types of skin and blood cancers. The main goal is to create a tool that helps doctors predict how different patients will respond to treatment based on specific factors. By collecting data from various hospitals, researchers aim to identify which patients have a better or worse chance of survival, allowing for more personalized care and improved outcomes.

To participate in this study, you must have been diagnosed with an advanced stage of mycosis fungoides or Sezary syndrome within the last six months. The trial is looking for patients who will receive ongoing care at the participating center, where they can gather important follow-up information. However, if you were diagnosed with an earlier stage of the disease, or if your diagnosis was made more than six months ago, you would not be eligible for this trial. Participants can expect to contribute important information that could help enhance treatment approaches for future patients with these conditions.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
• • Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available
• • Exclusion Criteria
• • Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
• • Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
• • Exclude one-time consultation type of new patients.